The Chanhassen-based company plans to use the funds on a randomized trial of its “sonodynamic therapy” for glioblastoma.

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical, Inc. (NYSE: GMED) announced that its Board of Directors has authorized a share repurchase program of up to ...

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 ...

Globus Medical’s board of directors authorized a share repurchase program of up to $500 million of the company’s outstanding common stock. Timing and number of repurchased shares will be determined by ...